Core Viewpoint - Galapagos NV (GLPG) has experienced significant selling pressure, resulting in a 21.2% decline over the past four weeks, but analysts anticipate better earnings than previously expected, indicating potential for recovery [1]. Technical Analysis - The Relative Strength Index (RSI) is utilized to determine if GLPG is oversold, with a current RSI reading of 19.28 suggesting that selling pressure may be exhausting, paving the way for a potential rebound [2][5]. - Stocks oscillate between overbought and oversold conditions, and the RSI helps identify price reversal points, indicating that GLPG may be undervalued due to excessive selling [3]. Fundamental Analysis - There has been a strong consensus among sell-side analysts to raise earnings estimates for GLPG, leading to a 34.3% increase in the consensus EPS estimate over the last 30 days, which typically correlates with price appreciation [6]. - GLPG holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, further supporting the stock's potential for a turnaround [7].

Deal Overview - Galapagos NV plans to split into two listed entities by mid-2025, creating a new entity focused on innovative medicines, referred to as SpinCo, which will concentrate on oncology, immunology, and virology [1][7] - The remaining Galapagos entity will specialize in cell therapy, particularly its lead CAR-T candidate, GLPG5101, for non-Hodgkin lymphoma [2][10] - Both companies will be listed on Euronext, with Gilead Sciences holding approximately 25% of shares in both entities post-split [3][9] Strategic Rationale - The separation is deemed a crucial move to unlock substantial value for shareholders and position Galapagos for sustainable growth [4][9] - SpinCo will receive around $2.5 billion from Galapagos to focus on building a pipeline of innovative medicines through strategic business development [5][13] - The reorganization follows a significant decline in company value, with over 90% correction since 2020 due to clinical trial setbacks and the impact of the COVID-19 pandemic [8][10] Financial Overview - Galapagos expects to have about €500 million in cash post-separation, aiming to address unmet medical needs through its cell therapy pipeline [10][11] - The company anticipates a normalized annual cash burn between €175 million and €225 million, excluding restructuring costs [12] - In FY23, total revenue declined 0.6% YoY to €239.7 million, with collaboration revenues amounting to €239.7 million [26] Workforce and Operations - The reorganization will lead to a reduction of around 300 positions in Europe, representing approximately 40% of the workforce [3][11] - Galapagos plans to discontinue its small molecule discovery programs and seek partners for its small molecule assets [11][19] Research and Development Focus - Galapagos will continue to advance its cell therapy platform, particularly in oncology, while SpinCo will focus on acquiring and developing innovative therapies in oncology, immunology, and virology [10][28] - The company has a robust pipeline of CAR-T therapies and over 15 discovery programs in immunology and oncology [20][21]

Strategic Reorganization and Separation - Galapagos plans to separate into two entities: Galapagos, focusing on cell therapy leadership in oncology, and SpinCo, dedicated to building a pipeline of innovative medicines through transformational transactions [1][4] - SpinCo will be capitalized with approximately €2.45 billion in cash and will focus on oncology, immunology, and virology through strategic business development transactions [4] - Galapagos will gain full global development and commercialization rights to its pipeline, subject to single-digit royalties to Gilead on net sales of certain products [2][5] Corporate Structure and Shareholder Impact - Gilead will hold approximately 25% of the outstanding shares in both Galapagos and SpinCo post-separation, with lock-up periods until March 31, 2027, for Galapagos and six months for SpinCo [7] - All Galapagos shareholders will receive shares of SpinCo on a pro rata basis based on their holdings as of a record date [6] - Gilead will nominate two Directors to the SpinCo Board, which will be majority independent [7] Financial and Operational Focus - Galapagos expects its normalized annual cash burn to be between €175 million and €225 million post-reorganization, excluding restructuring costs [12] - The company plans to discontinue its small molecule discovery programs and seek partners for its small molecule assets, including the TYK2 inhibitor GLPG3667 [10] - Galapagos will reduce approximately 300 positions, representing 40% of its workforce, primarily in Europe, to focus on long-term value creation in cell therapy [11] Strategic Vision and Leadership - The separation aims to unlock shareholder value by allowing Galapagos to focus on cell therapy in oncology while SpinCo pursues innovative therapies through strategic transactions [3][8] - Galapagos' lead CAR-T candidate, GLPG5101, has shown encouraging efficacy and safety in relapsed/refractory non-Hodgkin lymphoma, supporting its decentralized cell therapy manufacturing platform [9] - The reorganization is expected to position Galapagos for sustainable growth and future success in cell therapies [13] Transaction Process and Timeline - The separation is subject to customary conditions, including consultations with works councils and shareholder approval, with completion expected by mid-2025 [15] - Goldman Sachs International and Lazard acted as financial advisors, while Baker McKenzie and Allen Overy Shearman Sterling provided legal counsel [16] Industry and Market Implications - The separation allows investors to assess the distinct value propositions of Galapagos and SpinCo, enabling targeted investment strategies based on each entity's focus [14] - SpinCo's focus on innovative medicines and strategic transactions aligns with emerging trends in biotechnology and high unmet medical needs [4][8]

Mechelen, Belgium; January 7, 2025, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that the Company will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025, at 1:30 pm PT in San Francisco.A live webcast of the presentation will be accessible on the Investors page of the Company’s website at www.glpg.com/investors. A replay of the webcast will be available following the completion of the event and will be archived for up to 30 days.In addition, Gala ...

EXHIBIT 99.1 Galapagos Reports Third Quarter 2024 Financial Results and Provides Business Update We are advancing our pipeline and accelerating innovation through focused execution of our Forward, Faster strategy. We are committed to addressing the high unmet needs of patients through a growing cell therapy and small molecule pipeline with breakthrough potential. This includes more than 20 programs, with four assets in clinical development across 11 indications, and more than 15 preclinical programs in onco ...

We are advancing our pipeline and accelerating innovation through focused execution of our Forward, Faster strategy. We are committed to addressing the high unmet needs of patients through a growing cell therapy and small molecule pipeline with breakthrough potential. This includes more than 20 programs, with four assets in clinical development across 11 indications, and more than 15 preclinical programs in oncology and immunology. We achieved a major regulatory milestone with the FDA clearance of the Inves ...

Board Appointment - Oleg Nodelman appointed as Non-Executive Non-Independent Director to Galapagos' Board of Directors, effective October 7, 2024 [1] - Mr Nodelman replaces Dan G Baker who stepped down on October 6, 2024 [2] - Mr Nodelman is the Founder and Portfolio Manager of EcoR1 Capital LLC, a biotech-focused investment advisory firm [3] - Mr Nodelman holds a Bachelor of Science in Foreign Service with a concentration in Science and Technology from Georgetown University [4] Strategic Impact - The addition of Mr Nodelman marks an important step in Galapagos' ongoing efforts to engage with shareholders and continue to execute on the Forward, Faster strategy to accelerate innovation and create near-and long-term value [2] - Mr Nodelman's deep expertise in biotech and shared goals of unlocking further value for Galapagos will be instrumental in helping the company execute its near- and long-term strategy and deliver superior results for patients, shareholders, employees, and customers [3] - Mr Nodelman brings a wealth of experience in driving shareholder value, strategic transformations, and long-term growth initiatives [3] Company Overview - Galapagos is a biotechnology company with operations in Europe and the US dedicated to transforming patient outcomes through life-changing science and innovation [6] - The company focuses on high unmet medical needs and synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of best-in-class small molecules and cell therapies in oncology and immunology [6] - Galapagos has capabilities from lab to patient, including a decentralized cell therapy manufacturing platform, and the financial strength to invest strategically for the long-term [6]

Mechelen, Belgium; 16 September 2024, 22:01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) received a transparency notification from EcoR1 Capital LLC. Pursuant to Belgian transparency legislation1, Galapagos received a transparency notification on 13 September 2024 on behalf of Mr. Oleg Nodelman and EcoR1 Capital LLC, who notified that EcoR1 Capital LLC holds 6,713,553 of Galapagos' voting rights, consisting of 839,388 ordinary shares and 5,874,165 American Depository Receipts, further ...

Core Viewpoint - Shares of Galapagos NV are experiencing a rise following FDA clearance for its investigational new drug application for GLPG5101, aimed at treating relapsed/refractory non-Hodgkin lymphoma [1] Company Overview - Galapagos NV is a clinical-stage company focused on developing innovative therapies, including GLPG5101, an autologous CD19 CAR-T cell therapy administered as a single intravenous dose [2] - The company has a robust pipeline that includes small molecules and cell therapies in oncology and immunology, with ongoing studies for other candidates targeting leukemia and myeloma [7] Clinical Study Details - The ATALANTA-1 study will assess the feasibility, safety, and efficacy of GLPG5101 for relapsed/refractory non-Hodgkin lymphoma in the U.S., with early data from ongoing EU studies showing promising results [3][5] - The phase I portion of the trial aims to evaluate safety and initial effectiveness to determine appropriate dosage, while the phase II portion will focus on the objective response rate and other secondary outcomes [4][5] Market Performance - Year to date, shares of Galapagos have declined by 38.8%, contrasting with a 1.6% growth in the industry [5]

Mechelen, Belgium; 20 August 2024, 22:01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) received a transparency notification from FMR LLC. Pursuant to Belgian transparency legislation1, Galapagos received a transparency notification on 16 August 2024 from FMR LLC, who notified that it holds 3,696,750 of Galapagos' voting rights, consisting of 3,693,550 ordinary shares and 3,200 equivalent financial instruments. FMR LLC controls investment funds Fidelity Management & Research Company LLC ...